• LOGIN
    Login with username and password
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publications
  • Theses
  • Research Data
  • Projects
  • Organizations
  • Researchers
  • More
  • Collections
  • Statistics
  • LOGIN
    Login with username and password
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
 

Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.

Options
  • Details
  • Files
BORIS DOI
10.7892/boris.133286
Publisher DOI
10.1089/thy.2018.0555
PubMed ID
30938231
Description
Background:
Anaplastic thyroid carcinoma (ATC) is one of the most aggressive human cancers, with a median survival of only three to six months. Standard treatment options and even targeted therapies have so far failed to improve long-term overall survival. Thus, novel treatment modalities for ATC, such as immunotherapy, are urgently needed. CD47 is a "don't eat me" signal, which prevents cancer cells from phagocytosis by binding to signal regulatory protein alpha on macrophages. So far, the role of macrophages and the CD47-signal regulatory protein alpha signaling axis in ATC is not well understood.
Methods:
This study analyzed 19 primary human ATCs for macrophage markers, CD47 expression, and immune checkpoints by immunohistochemistry. ATC cell lines and a fresh ATC sample were assessed by flow cytometry for CD47 expression and macrophage infiltration, respectively. CD47 was blocked in phagocytosis assays of co-cultured macrophages and ATC cell lines. Anti-CD47 antibody treatment was administered to ATC cell line xenotransplanted immunocompromised mice, as well as to tamoxifen-induced ATC double-transgenic mice.
Results:
Human ATC samples were heavily infiltrated by CD68- and CD163-expressing tumor-associated macrophages (TAMs), and expressed CD47 and calreticulin, the dominant pro-phagocytic molecule. In addition, ATC tissues expressed the immune checkpoint molecules programmed cell death 1 and programmed death ligand 1. Blocking CD47 promoted the phagocytosis of ATC cell lines by macrophages in vitro. Anti-CD47 antibody treatment of ATC xenotransplanted mice increased the frequency of TAMs, enhanced the expression of macrophage activation markers, augmented tumor cell phagocytosis, and suppressed tumor growth. In double-transgenic ATC mice, CD47 was expressed on tumor cells, and blocking CD47 increased TAM frequencies.
Conclusions:
Targeting CD47 or CD47 in combination with programmed cell death 1 may potentially improve the outcomes of ATC patients and may represent a valuable addition to the current standard of care.
Date of Publication
2019-07
Publication Type
Article
Subject(s)
500 Science > 570 Life sciences; biology
600 Technology > 610 Medicine & health
500 Science > 540 Chemistry
Keyword(s)
CD47 anaplastic thyroid carcinoma immune checkpoints phagocytosis programmed cell death 1 tumor-associated macrophages
Language(s)
en
Contributor(s)
Schürch, Christian M
Rölli, Matthias Andreas
Institut für Biochemie und Molekulare Medizin (IBMM)
Forster, Stefan
Institut für Pathologie
Wasmer, Marie-Hélène Christin
Institut für Pathologie
Brühl, Frido
Institut für Pathologie
Maire, Renaud Sylvain
Institut für Pathologie, Endokrine Pathologie
Di Pancrazio, Sergio
Ruepp, Marc-David
Departement für Chemie und Biochemie (DCB)
Giger, Roland
Universitätsklinik für Hals-, Nasen- und Ohrenkrankheiten, Kopf- und Halschirurgie (HNOK)
Perren, Aurelorcid-logo
Institut für Pathologie
Schmitt Kurrer, Anja
Institut für Pathologie
Krebs, Philippeorcid-logo
Institut für Pathologie, Immunpathologie
Charles, Roch-Philippeorcid-logo
Institut für Biochemie und Molekulare Medizin (IBMM)
Dettmer, Matthiasorcid-logo
Institut für Pathologie
Additional Credits
Institut für Biochemie und Molekulare Medizin (IBMM)
Institut für Pathologie
Institut für Pathologie, Endokrine Pathologie
Departement für Chemie und Biochemie (DCB)
Universitätsklinik für Hals-, Nasen- und Ohrenkrankheiten, Kopf- und Halschirurgie (HNOK)
Institut für Pathologie, Immunpathologie
Series
Thyroid
Publisher
Mary Ann Liebert
ISSN
1050-7256
Access(Rights)
open.access
Show full item
BORIS Portal
Bern Open Repository and Information System
Build: dd892c [ 9.04. 8:30]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
  • Audiovisual Material
  • Software & other digital items
  • Events
More
  • About BORIS Portal
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo